Ani Pharmaceuticals (ANIP) Accounts Payables (2016 - 2025)
Ani Pharmaceuticals (ANIP) has disclosed Accounts Payables for 16 consecutive years, with $62.6 million as the latest value for Q4 2025.
- Quarterly Accounts Payables rose 37.08% to $62.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $62.6 million through Dec 2025, up 37.08% year-over-year, with the annual reading at $62.6 million for FY2025, 37.08% up from the prior year.
- Accounts Payables hit $62.6 million in Q4 2025 for Ani Pharmaceuticals, down from $69.8 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $69.8 million in Q3 2025 to a low of $11.5 million in Q3 2021.
- Historically, Accounts Payables has averaged $36.8 million across 5 years, with a median of $33.4 million in 2023.
- Biggest five-year swings in Accounts Payables: dropped 14.47% in 2021 and later soared 113.0% in 2022.
- Year by year, Accounts Payables stood at $23.0 million in 2021, then rose by 27.6% to $29.3 million in 2022, then increased by 25.18% to $36.7 million in 2023, then rose by 24.46% to $45.7 million in 2024, then soared by 37.08% to $62.6 million in 2025.
- Business Quant data shows Accounts Payables for ANIP at $62.6 million in Q4 2025, $69.8 million in Q3 2025, and $54.6 million in Q2 2025.